List view / Grid view
Discover how Domain Therapeutics is using its deep knowledge of GPCR biology to create novel therapeutics with the potential to combat inflammatory diseases such as atopic dermatitis, IBD and arthritis.
We had the privilege of speaking to Dr Mark R. Kelley, Associate Director of Basic Science at the Indiana University Melvin and Bren Simon Comprehensive Cancer Center, and Betty and Earl Herr Professor in Pediatric Oncology Research, prior to his talk at PharmSci 360 in 2024. He elucidates what makes…
Intestinal epithelial organoids highlight a pathway implicated in CD, named major histocompatibility complex (MHC)-I.
Researchers have identified a new biological pathway driving IBD and similar conditions that could be targeted with MEK inhibitors.
Through in vitro and in vivo models, researchers find a mechanism by which bacteria-generated fatty acids regulate immune responses.
A new approach called reverse metabolomics has discovered molecules that may serve as a biomarker or a therapeutic target for IBD.
A technique that can sort millions of CRISPR-edited cells based on their secretion patterns has been developed to treat autoimmune diseases.
Researchers have developed organoids with naturally occurring early-stage immune cells, which could lead to effective personalised treatment.
An increasing number of people worldwide suffer from inflammatory bowel disease (IBD). However, no treatment is effective for all patients. In this article, researchers working on the Algae4IBD project explain how algae may represent a valuable source of prebiotics and new therapeutic agents for IBD and other diseases.
New research from Cincinnati Children’s Hospital Medical Center suggests blocking IL-22 and IL-1R could offer a promising IBD treatment.
Researchers from the University of Pennsylvania have developed a novel organ-on-a-chip technology called OCTOPUS, an optimised device for growing mini-organs in a dish.
US researchers have uncovered the uncapped potential that gut-friendly bacteria has for improving treatments of inflammatory bowel disease (IBD).
Dr Christopher Locher, Versatope Therapeutics, explains why bacterial extracellular vesicles are ideally suited for recombinant vaccines because target antigens can be expressed as fusion proteins and targeted to the lumen, membrane or surface of the vesicles. These nano-size vesicles represent a potentially safe and simple subunit vaccine delivery platform that…
Researchers at Synlogic are clearing the path for a new class of medicine – biotherapeutics based on synthetic biology, called synthetic biotics, which are created by programming or engineering bacteria to metabolise or secrete well-validated targets of disease pathophysiology. In this article, Dr Caroline Kurtz, Chief Development Officer at Synlogic, discusses how synthetic…
Researchers have succeeded in developing organoids that contain mature Paneth cells, which were not present in the previous human small intestinal organoids.
